Navigation Links
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
Date:11/15/2011

in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc., including statements about its development programs, proposed indications for its product candidates, pre-clinical activities, clinical trials and clinical trial results, collaborations with others, potential collaborations or agreements on its product candidates, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements. Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of clinical trials, regulatory actions by the Food and Drug Administration and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release. PALATIN TECHNOLOGIES, INC.and SubsidiaryConsolidated Statement of Operations(unaudited)Three Months Ended September 30,20112010REVENUES$
27,217$
216,147O
'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... group leader Yung-Eun Sung has announced that they ... nitrogen-doped graphenes which can be applied as high ... Yung-Eun Sung is both a group leader at ... Basic Science* (IBS) and a professor at the ... significance with regards to the development of relative ...
(Date:7/24/2014)... July 24, 2014 Research and Markets ... Cell Culture Market 2014-2018" report to their offering.  ... Cell culture is the in vitro growth of plant ... cell studies, and biopharmaceutical production. Cell culture is a ... culture instruments and cell culture consumables are necessary for ...
(Date:7/24/2014)... , July 24, 2014  CorMedix Inc. (NYSE ... and commercializing therapeutic products for the prevention and ... receipt of notice on July 18, 2014 from ... has accepted the CorMedix plan to regain compliance ... a result, the NYSE-MKT is continuing the Company,s ...
(Date:7/24/2014)... WIRB-Copernicus Group ® ("WCG")™, the ... services for clinical research, announced today that it ... Richmond, VA -based Alliance Engineering, ... consulting firm in the United States ... – WCG Biosafety™ – will be able to ...
Breaking Biology Technology:Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3
... the Beijing Genomics Institute), the largest genomics organization in ... of Sciences, together published the whole sequence variation map ... Genome Biology on July 6th, 2011 ( http://genomebiology.com/2011/12/7/R63 ... biomedical research. Rhesus macaque, also called the Rhesus ...
... 2011 America,s #1 rated morning news program, The ... a blood test that measures cellular aging.  The segment entitled ... Test as a tool for those interested in monitoring their ... Test measures a person,s biological age in comparison to their ...
... RIDGEFIELD, Conn., July 21, 2011 Boehringer Ingelheim ... etexilate mesylate) capsules has been added to hospital formularies at ... as ranked by U.S. News & World Report,s ... approved by the U.S. Food and Drug Administration (FDA) to ...
Cached Biology Technology:Whole sequence variation map reveals insight into evolutionary studies of rhesus macaque 2SpectraCell's Telomere Testing Goes Mainstream 2SpectraCell's Telomere Testing Goes Mainstream 3Pradaxa® (dabigatran etexilate mesylate) Capsules Now on Formulary at Nation's Top Heart Hospitals 2Pradaxa® (dabigatran etexilate mesylate) Capsules Now on Formulary at Nation's Top Heart Hospitals 3Pradaxa® (dabigatran etexilate mesylate) Capsules Now on Formulary at Nation's Top Heart Hospitals 4Pradaxa® (dabigatran etexilate mesylate) Capsules Now on Formulary at Nation's Top Heart Hospitals 5Pradaxa® (dabigatran etexilate mesylate) Capsules Now on Formulary at Nation's Top Heart Hospitals 6
(Date:7/24/2014)... effects on different species of fish, according to ... and Exeter which tested fish anti-predator behaviour. ... seagull predator model when exposed to additional noise, ... , Lead author Dr Irene Voellmy of ... in many aquatic environments have increased substantially during ...
(Date:7/24/2014)... ply silent freeways, solar panels blanket rooftops and power ... howling winds and from the blazing desert sun. , ... and economically feasible to convert California,s all-purpose energy infrastructure ... Energy , the plan shows the way to ... that could create tens of thousands of jobs and ...
(Date:7/24/2014)... 24, 2014 Some sticky research out of York ... a certain species of toxic grass fungus: moose saliva ... Biology Letters , "Ungulate saliva inhibits a grassendophyte ... to red fescue grass (which hosts a fungus called ... slower fungus growth and less toxicity. , "Plants have ...
Breaking Biology News(10 mins):Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4Moose drool inhibits growth of toxic fungus: York U research 2
... Meteorological Institute in Helsinki, Finland, will host the first ... Cloud Climate and Air Quality Interactions, EUCAARI, headed by ... purpose of EUCAARI is to significantly improve current knowledge ... on climate and air quality. The first year of ...
... and Profit Growth, WALL, N.J., Nov. 14 ... leader in wireless public safety and,finger-based biometric identification ... quarter ended September 30, 2007. Total revenue ... 30, 2007 was $2.2 million representing a 27% ...
... that males evolve more quickly than females has been ... majesty of a peacocks tail feather in comparison with ... species, males apparently ramp up flashier features and more ... best mates, a concept known as sexual selection. ...
Cached Biology News:Worldwide atmospheric measurements will determine the role of atmospheric fine particles 2BIO-key Reports Third Quarter 2007 Results 2BIO-key Reports Third Quarter 2007 Results 3BIO-key Reports Third Quarter 2007 Results 4BIO-key Reports Third Quarter 2007 Results 5Simple reason helps males evolve more quickly 2Simple reason helps males evolve more quickly 3
Agarose Gel Loading Dye Mixture 6X...
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
...
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
Biology Products: